Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
The CheckMate 7FL trial investigated the effectiveness of adding ...
CheckMate 7FL Neoadjuvant Immunochemotherapy in ER-Positive, HER2 ...
ホルモン陽性HER2陰性乳癌に対しての術前化学療法+ニボルマブ CheckMate 7FL | 乳がん論文備忘録
CheckMate 7LF: Avaliação da combinação de nivolumabe e quimioterapia ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
CheckMate 77T Trial: Perioperative Nivolumab Plus Chemotherapy in Stage ...
FDA Approval: Perioperative Nivolumab + Chemotherapy - CheckMate 77T ...
Neoadjuvant Nivolumab Plus Chemotherapy in Lung Cancer: CheckMate 816 ...
CheckMate 77T QOL Data Further Support Perioperative Nivolumab in ...
CheckMate 7FL: nivo vs PBO in high-risk ER+ HER2- BC with neoadjuvant ...
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent ...
CheckMate 77T Trial of Perioperative Nivolumab Generates EFS Benefit in ...
CheckMate 577 Final Results: Adjuvant Nivolumab Sustains Disease-Free ...
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial | AJMC
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 ...
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 ...
(PDF) First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate ...
Subcutaneous Nivolumab checkMate -67T trial demonstrates noninferiority ...
Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer
A trial of nivolumab before and after surgery for breast cancer ...
宋国红教授：2023 年度进展盘点之HR阳性乳腺癌_腾讯新闻
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate ...
Skuteczność nivolumabu w zwiększaniu pCR w raku piersi ER+/HER2− ...
Análise exploratória de biomarcadores em câncer de mama primário ER+ ...
Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant ...
ESMO 2023丨在HR阳性早期乳腺癌中，新辅助治疗中加入免疫治疗相关研究首次显示患者有显著获益-肿瘤瞭望
Abstract GS01-01: Biomarker Results in High-risk Estrogen Receptor ...
ER+/HER2-乳がんの術前ニボルマブ、pCRを有意に改善（CheckMate 7FL）／ESMO2023｜医師向け医療ニュースはケアネット
CheckMate-77T: A Deeper Look at a Nivolumab-Based Regimen in NSCLC ...
A phase III trial of nivolumab with neoadjuvant chemotherapy and ...
ESMO Virtual Congress 2020: First Results From the Randomized Phase 3 ...
Neoadjuvant Nivolumab Plus Chemotherapy in Resectable Lung Cancer ...
Nivolumab for previously treated non-small-cell lung cancer-CheckMate ...
134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and ...
CheckMate-067: 6.5-Year Follow-up Shows Durable Benefit With Nivolumab ...
First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus ...
ASCO 2025: Nivolumab plus Ipilimumab vs Sunitinib for First-Line ...
(PDF) Nivolumab adjuvant therapy for esophageal cancer: a review based ...
Frontiers | Nivolumab adjuvant therapy for esophageal cancer: a review ...
Neoadjuvant Nivolumab Improves pCR in ER+/HER2- Breast Cancer - Cancer ...
Neoadjuvant nivolumab plus chemotherapy in resectable non‐small‐cell ...
Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell ...
(PDF) First-Line Nivolumab Plus Ipilimumab With Chemotherapy for ...
Nivolumab adjuvant therapy for esophageal cancer: a review based on ...
Nivolumab plus chemotherapy in first-line metastatic non-small-cell ...
Adjuvant nivolumab improves disease-free survival in patients with ...
(PDF) Safety and efficacy of nivolumab plus ipilimumab in patients with ...
(PDF) Nivolumab plus radiotherapy with or without temozolomide in newly ...
(PDF) First-line nivolumab plus ipilimumab combined with two cycles of ...
Four-year clinical update and treatment switching-adjusted outcomes ...
First-line nivolumab plus ipilimumab combined with two cycles of ...
(PDF) Nivolumab in patients with advanced hepatocellular carcinoma ...
(PDF) Adjuvant therapy with nivolumab versus placebo in patients with ...
Nature Medicine：Nivolumab联合化疗：乳腺癌患者的新希望还是挑战？-MedSci.cn
First-line nivolumab plus ipilimumab with two cycles of chemotherapy ...
(PDF) Adjuvant nivolumab in resected stage IIB/C melanoma: primary ...
ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line ...
(PDF) First-line nivolumab plus ipilimumab with two cycles of ...
ASCO 2024: Subcutaneous Nivolumab Versus Intravenous Nivolumab in ...
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with ...
(PDF) First-line nivolumab plus ipilimumab or chemotherapy versus ...
PL02.08 Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC ...
ESMO 2022: Tumor and Immune Features Associated with Disease-Free ...
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal ...
OPDIVO® (nivolumab) for the Adjuvant Treatment of High-Risk Urothelial ...
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes ...
(PDF) CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy ...
(PDF) Nivolumab Plus Low-Dose IPILIMUMAB as First-Line Treatment of ...
Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen ...
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus ...
First-line nivolumab plus chemotherapy versus chemotherapy alone for ...
Highlights on 1L nivolumab + chemo for metastatic urothelial carcinoma ...
ELCC 2023: Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C ...
CheckMate-77T Update: Nivolumab-Based Regimen Improves EFS in NSCLC
(PDF) Publisher Correction: Adjuvant nivolumab in resected stage IIB/C ...
Nivolumab Combos Explored in First-Line NSCLC Trial
(PDF) Efficacy of Nivolumab for Head and Neck Cancer Patients with ...
.png)
30641-0/asset/58152fdc-1b05-44e3-8d75-6c64df3d642f/main.assets/gr1.gif)
